Hib-DTP-acellular poliovirus vaccine (Sanofi)

吸附无细胞百白破灭活脊髓灰质炎和b型流感嗜血杆菌(结合)联合疫苗（赛诺菲）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHib-DTP-acellular poliovirus vaccine (Sanofi)
Drug Alias Name白喉、破伤风类毒素、无细胞百日咳吸附、灭活脊髓灰质炎病毒和嗜血杆菌b缀合物（破伤风毒素结合物）疫苗 （赛诺菲）DTaP-IPV-Hib (sanofi pasteur)Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) vaccine and Haemophilus type b conjugate (Sanofi)PentacelPediacel +[9] 
ClassificationVaccines > Biological material > Viral vaccineVaccines > Biological material > Bacterial vaccineVaccines > Vaccine type > Combination vaccine +[7] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsRotavirus InfectionsHepatitis BPoliomyelitis, Bulbar +[10] 
Global Approved IndicationsPoliomyelitis, BulbarPoliomyelitisTetanus +[6] 
Approved Indications in ChinaPoliomyelitis, BulbarTetanusDiphtheria +[5] 
Original Approved Country/TerritoryUnited States
Original Approved Date2008/06/24
Country/TerritoryUnited StatesSwedenNetherlands +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesSanofi Pasteur
Inactive CompaniesGlaxosmithkline PlcSanofi
Active IndicationsPoliomyelitis, BulbarPoliomyelitisTetanus +[6] 
Inactive IndicationsRotavirus InfectionsHepatitis BStreptococcal Infections +[4] 

Other Information

ATC CodeJ07CA06
Related LinksN/A